In the third-line setting , for patients who have not received erlotinib or gefitinib , treatment with erlotinib is recommended .
There are insufficient data to recommend routine third-line cytotoxic therapy .
Purpose To provide evidence -based recommendations to up date the American Society of Clinical Oncology guideline on systemic therapy for stage IV non – small-cell lung cancer ( NSCLC ) .
Results This guideline up date reflects changes in evidence since the previous guideline .
Impact of an inpatient palliative care team: a randomized control trial.
BACKGROUND Palliative care improves care and reduces costs for hospitalized patients with life-limiting illnesses . There have been no multicenter r and omized trials examining impact on patient satisfaction , clinical outcomes , and subsequent health care costs . OBJECTIVE Measure the impact of an interdisciplinary palliative care service ( IPCS ) on patient satisfaction , clinical outcomes , and cost of care for 6 months posthospital discharge . METHODS Multicenter , r and omized , controlled trial . IPCS provided consultative , interdisciplinary , palliative care to intervention patients . Controls received usual hospital care ( UC ) . SETTING AND SAMPLE Five hundred seventeen patients with life-limiting illnesses from a hospital in Denver , Portl and , and San Francisco enrolled June 2002 to December 2003 . MEASURES Modified City of Hope Patient Question naire , total health care costs , hospice utilization , and survival . RESULTS IPCS reported higher scores for the Care Experience scale ( IPCS : 6.9 versus UC : 6.6 , p = 0.04 ) and for the Doctors , Nurses/Other Care Providers Communication scale ( IPCS : 8.3 versus UC : 7.5 , p = 0.0004 ) . IPCS patients had fewer intensive care admissions ( ICU ) on hospital readmission ( 12 versus 21 , p = 0.04 ) , and lower 6-month net cost savings of $ 4,855 per patient ( p = 0.001 ) . IPCS had longer median hospice stays ( 24 days versus 12 days , p = 0.04 ) . There were no differences in survival or symptom control . CONCLUSIONS IPCS patients reported greater satisfaction with their care experience and providers ' communication , had fewer ICU admissions on readmission , and lower total health care costs following hospital discharge
In the third-line setting , for patients who have not received erlotinib or gefitinib , treatment with erlotinib is recommended .
There are insufficient data to recommend routine third-line cytotoxic therapy .
Purpose To provide evidence -based recommendations to up date the American Society of Clinical Oncology guideline on systemic therapy for stage IV non – small-cell lung cancer ( NSCLC ) .
Results This guideline up date reflects changes in evidence since the previous guideline .